ArticleDiscover oncology2025
A case of metachronous cervical and early-stage breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction: A case of metachronous cervical and early-stage breast cancer.Discover oncology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCervical and breast cancer are among the most common malignancies in women, typically presenting independently. Their concurrent or metachronous occurrence is rare due to differing etiological factors. This report presents the case of a 53-year-old woman diagnosed with recurrent metastatic cervical cancer who subsequently developed early-stage breast cancer. CASE PRESENTATION: A 53-year-old postmenopausal woman with a history of cervical cancer, treated with radical hysterectomy and chemoradiotherapy in 2001, developed a pelvic wall recurrence with distant metastases in 2022. Despite treatment with chemotherapy in combination with checkpoint inhibitor pembrolizumab and subsequent Tisotumab Vedotin, her three-month follow-up in August 2024 revealed a new lesion in the right breast which turned out to be breast cancer. Biopsy confirmed a well-differentiated, hormone receptor-positive, HER2-negative breast cancer with a low proliferation index of 10%. DISCUSSION: The simultaneous or sequential presentation of cervical and breast cancer is rare, especially under systemic treatment. The patient's cervical cancer was aggressive, and the subsequent metachronous breast cancer highlights the complex, multifactorial nature of carcinogenesis. The development of a second primary malignancy while a patient is receiving treatment for a metastatic condition is a critical clinical scenario, necessitating individualized treatment strategies, as optimal management remains unclear due to the rarity of such cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.